SLC5A2 and steatosis: For example, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide improve hepatic outcomes primarily through weight loss and glycemic control, whereas sodium-glucose cotransporter-2 (SGLT2) inhibitors improve steatosis, fibrosis, and liver enzymes primarily via weight reduction, visceral fat loss, and improved glycemia [29,30].